ClinicalTrials.gg
RecruitingNCT06431633ARIANUpdated May 18, 2026

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

A Phase 3 interventional study of Zimberelimab and Sacituzumab govitecan in Lung Diseases, Carcinoma, Non-Small-Cell Lung and Resectable Lung Non-Small Cell Carcinoma, sponsored by Fundación GECP. Recruiting at 32 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación GECP · Phase 3, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, 2 of them phase 3. zimberelimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
7th of 10
129 · median 152
Started
2025
the only one that year
Phase 3
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Fundación GECP

Among the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 3, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About zimberelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Open-label, phase III, randomized, stratified (PDL1- vs PDL1+), 3 arms, multicenter clinical trial.

129 resected patients (43 per arm) with stage from IB to IIIA and IIIB (N2) non-small cell lung cancer that do not achieve pathologic complete response (pCR) after neoadjuvant treatment.

This clinical trial has 3 arms of treatment. ARM 1: Observation 10 months, ARM 2: treatment with immunotherapy (Zimberelimab) for 13 cycles and ARM 3: treatment with Sacituzumab Govitecan and Zimberelimab for 8 cycles and Zimberelimab monotherapy for 5 cycles.

The primary objective is to evaluate the disease-free survival (DFS): defined as the length of time from randomization to the earliest event defined as disease recurrence, any new lung cancer (even in the opposite lung), or death from any cause at any known point in time.

Patient accrual is expected to be completed within 2 years, treatment is planned to extend during 1 years and the patients will be followed up for 2 years. The study will end once survival follow-up has concluded.

Read the detailed description

This is an open-label, phase III, randomized, stratified (PDL1- vs PDL1+), 3 arms, multicenter clinical trial.

Patients stage IB to IIIA-IIIB (T3N2) after surgical resection if they did not achieve a pathological com-plete response (pCR) will be randomized 1:1:1 to:

  • ARM 1: Observational Arm for 10 months
  • ARM 2: Immunotherapy (Zimberelimab) treatment for 13 cycles, Q3W
  • ARM 3: Sacituzumab Govitecan + Zimberelimab Q3W for 8 cycles + Zimberelimab Q3W for 5 cycles. Patients will receive 8 cycles of the combination and 5 cycles of Zimberelimab monotherapy.

The primary objective is to evaluate the disease-free survival (DFS): defined as the length of time from randomization to the earliest event defined as disease recurrence, any new lung cancer (even in the opposite lung), or death from any cause at any known point in time.

Disease Free survival (DFS): The time from random assignment to cancer recurrence or death from any cause.

Secondary objectives:

  • Overall survival (OS): at 12, 24 and 36 months after the start of adjuvant treatment
  • Safety and tolerability of the combination of Sacituzumab Govitecan + Zimberelimab according to CTCAE v5.0.

Exploratory objectives

- To evaluate whether there is a significant association between change in levels of ctDNA between baseline and after adjuvant treatment and OS and DFS.

The total trial duration will be 7 years approximately. Approval-start up: 4-6 months. Patient accrual is expected to be completed within 2 years. One year of treatment and 3 years of follow up, and close-out: 4-6 months. The study will end once survival follow-up has concluded

03

Conditions studied

  • Lung Diseases
  • Carcinoma, Non-Small-Cell Lung
  • Resectable Lung Non-Small Cell Carcinoma

Browse trials for

04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 129 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Fundación GECP is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patients diagnosed of primary non-small cell lung cancer, confirmed.
  • 2. Patients should be classified postoperatively in stage IB, IIA, IIB, IIIA or IIIB (N2) according to pathological criteria (pTNM) and according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology
  • 3. Complete surgical resection (R0) of the primary NSCLC is also essential. Surgeons are strongly advised to dissect or obtain samples of all accessible lymph node levels, as established in the European Society of Thoracic Surgeons guide. Consequently, at the end of the surgical intervention it is recommended to have obtained samples of a minimum of 3 specific mediastinal ganglionic lobe stations (N2), one of which should include station 7, and at least one N1 station
  • 4. The surgical intervention may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy, as determined by the responsible surgeon based on intraoperative findings. Patients who have had only segmentectomies or wedge resections are not considered eligible for participation in this study except if R0 resection can be confirmed.
  • 5. Only patients that do not achieve pathological complete response (pCR) seen in the surgical piece after therapy are eligible.
  • 6. Preoperative (neoadjuvant) use of platinum-based chemotherapy + immunotherapy (anti ) is mandatory.
  • 7. Preoperative, postoperative, or scheduled radiation therapy is not accepted for a later time. Patients with only N2 disease, who have to receive post-operative adjuvant radiotherapy will not be eligible.
  • 8. A minimum of 3 weeks must have elapsed between the surgical intervention performed for the NSCLC and the randomization. Adjuvant treatment must start between the 3rd and the 10th week from surgery.
  • 9. (ECOG) performance status 0-1
  • 10. Patients aged ≥ 18 years.
  • 11. PDL1 value analysed locally (hospital must be able to provide this value before randomization)
  • 12. PET-CT and brain CT before randomization to confirm the absence of distant disease.
  • 13. Adequate hematologic and organ function
  • 14.All patients are notified of the nature of this study and signed a written in-formed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.
  • 15.For female patients of , agreement (by patient and/or partner) to use a highly effective form(s) of
  • 16. For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception
  • 17. Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drugs.
  • 18.Women who are not or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.
  • 19.Patient capable of proper therapeutic compliance and accessible for correct follow-up
  • 20. Patients with a of at least more than 12 weeks

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with a history of other malignant diseases, with the exception of the following:

    • properly treated non-melanotic skin cancer
    • cancer in situ treated with curative intent or other treated with curative intent and without signs of disease for a period of> 3 years after the end of the treatment and which, in the opinion of the doctor in charge of their treatment, do not present a substantial risk of relapse of the previous malignant disease.
  • 2.T4 patients with invasion of heart, great vessels, carina, trachea, oesophagus or spine
  • 3. Patients with ALK translocation, STK11 o KEAP1 known mutations before inclusion in this trial.
  • 4. Patients with adenocarcinoma NSCLC must be tested for the common EGFR mutations before inclusion. Patients with any known EGFR mutation cannot be enrolled in the study.
  • 5. Patients with a combination of microcytic and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma
  • 6. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of randomization.
  • 7. Patients that received within 30 days prior to randomization
  • 8. History of a primary immunodeficiency, history of organ transplantation, use of drugs within 28 days before randomization or previous history of toxicity of severe immune mechanism (grade 3 or 4) with other immunological treatments
  • 9. Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol.
  • 10. Patients who have suffered untreated and / or uncontrolled cardiovascular disorders and / or who have symptomatic cardiac dysfunction
  • 11. Pregnant or breastfeeding women
  • 12. Patients in whom R0 resection cannot be confirmed.
  • 13. Patients with an active, known or suspected disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • 14.Patients with a condition requiring systemic treatment with either or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • 15. Have active virus (HBV) or virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
  • 16. History of allergy or to any of the study drug components
  • 17. Pleural or pericardial effusion, both will be considered indicative of disease unless proven otherwise. Patients with pleural effusion not visible on chest-X-ray or too small to perform diagnostic puncture safely may be included.
  • 18. Have known history of -1 or 2 with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
  • 19.Severe infections within 4 weeks prior to be included in the study, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
  • 20.Patients with medical, mental, neurological or psychological condition which in the opinion of the investigator would not permit the patient to understand the patient information sheet or comply with study procedures.
  • 21. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder; any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement; or prior pneumonectomy.
  • 22. Treatment with systemic immunosuppressive medications
  • 23.Patients with uncontrolled comorbidities that may affect the clinical trial compliance.
  • 24.Sexually active men and women of who are not willing to use an effective method during the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (estimated)

Study arms

  • Active comparator
    ARM 1: Observation-investigator decision

    Patients randomized in this arm will be in observation for 10 months. It is allowed to administer adjuvant treatment according to investigator criteria. Immunotherapy is not allowed in this arm, only chemotherapy treatment is allowed.

    Drug: Cisplatin · Drug: Carboplatin

  • Experimental
    ARM 2: Immunotherapy. Zimberelimab treatment for 13 cycles

    Adjuvant treatment with Zimberelimab will start between the 3rd to the 10th week from surgery. 13 cycles will be administered in total. Cycles will be administered in 21-day intervals (Q3W). Zimberelimab: day 1 360 mg IV Q3W (13 cycles)

    Drug: Zimberelimab

  • Experimental
    ARM 3: Sacituzumab Govitecan + Zimberelimab for 8 cycles + Zimberelimab for 5 cycles

    Sacituzumab Govitecan: day 1 and 8; 10mg/Kg IV Q3W Zimberelimab: day 1 360 mg IV Q3W Treatment sequence: Adjuvant treatment will start between the 3rd to the 10th week from surgery. 13 cycles will be administered in total. Cycles will be administered in 21-day intervals (Q3W). Patients will receive 8 cycles of Sacituzumab Govitecan + Zimberelimab and 5 cycles of Zimberelimab monotherapy.

    Drug: Zimberelimab · Drug: Sacituzumab govitecan

Interventions

  • Zimberelimab is a fully human IgG4 monoclonal antibody targeting human PD-1. PD-1 is a type I transmembrane protein that is part of the immunoglobulin gene superfamily and the CD28 family of cell surface receptors. PD-1 is an inhibitory immune checkpoint protein that is expressed on activated B cells, T cells, and myeloid cells, and it plays a key role in limiting the activity of effector T cells. Zimberelimab is formulated at 30 mg/mL in a buffer solution containing histidine/histidine-HCl buffer solution, sucrose, sodium chloride, and polysorbate 80, at pH 5.5. The investigational product is supplied as a vial contains 120 mg of active Zimberelimab at a concentration of 30mg/mL. No premedication nor profilaxis is needed before Zimberelimab administration. Zimberelimab doses are administered by IV infusion over 60 minutes, followed by a 30- to 60-minute observation period, on D1 of each 21-day cycle.

    Also known as: anti-PD-1 monoclonal antibody AB122

  • Sacituzumab govitecan (SG) is an ADC composed of the following 3 components: o The humanized monoclonal antibody hRS7 IgG1κ, which binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers. o The camptothecin-derived agent SN-38, a topoisomerase I inhibitor. o A hydrolyzable linker, with the company designation as CL2A that links the humanized monoclonal antibody to SN-38. Sacituzumab govitecan is approved globally for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and HR+ breast cancer.

    Also known as: Trodelvy

  • Cisplatin-based adjuvant chemotherapy Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation.

    Also known as: Platinol

  • Cisplatin-based adjuvant chemotherapy Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin. Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center. Other Name: ATC code: L01XA02

    Also known as: Paraplatin

07

What researchers measure

Primary outcomes

  1. Disease free survival

    Defined as the length of time from randomization to the earliest event defined as disease recurrence, any new lung cancer (even in the opposite lung), or death from any cause at any known point in time.

    Time frame: The time from random assignment to cancer recurrence or death from any cause, assessed up to 36 months

Secondary outcomes

  1. Overall survival

    defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.

    Time frame: To evaluate at 12, 24 and 36 months after the start of adjuvant treatment

  2. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Occurrence and severity of adverse events, with severity determined by NCI CTCAE v5.0 criteria.

    Time frame: From the subject's written consent to participate in the study through 180 days after the final administration of the drug

Other outcomes

  1. Change in levels of ctDNA during treatment

    Analyze plasma samples and quantifying the amount of circulating tumor DNA (ctDNA) by NGS.

    Time frame: To analyze at pretreatment, after 6 months of treatment, and at disease relapse, assessed up to 36 months

08

Study locations

31 of 32 sites recruiting
  • Hospital General Universitario de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • Bartomeu Massuti, MD · Contact
    • Bartomeu Massuti, MD · Principal investigator
  • Hospital General de Elche
    Elche, Alicante 03203, Spain
    Recruiting
    • Miguel Borregón Rivilla, MD · Contact
    • Miguel Borregón Rivilla, MD · Principal investigator
  • ICO Badalona, Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Marta Domenech, MD · Contact
    • Marta Domenech, MD · Principal investigator
  • Hospital Universitari Vall d' Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Alex Martínez, MD · Contact
    • Alex Martínez, MD · Principal investigator
  • Hospital Clínic De Barcelona
    Barcelona, Barcelona 08036, Spain
    Recruiting
    • Noemí Reguart · Contact
    • Noemí Reguart, MD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08041, Spain
    Recruiting
    • Andres Barba, MD · Contact
    • Andres Barba, MD · Principal investigator
  • Hospital Parc Taulí
    Barcelona, Barcelona 08208, Spain
    Recruiting
    • Laia Vilà, MD · Contact
    • Laia Vilà, MD · Principal investigator
  • ICO Hospitalet
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Ernest Nadal, MD · Contact
    • Ernest Nadal, MD · Principal investigator
  • Hospital De Basurto
    Bilbao, Bilbao 48013, Spain
    Recruiting
    • Mª Ángeles Sala, MD · Contact
    • Mª Ángeles Sala, MD · Principal investigator
  • Hospital Universitario Jerez De La Frontera
    Jerez de la Frontera, Cádiz 11407, Spain
    Recruiting
    • Mª Ángeles Moreno, MD · Contact
    • Mª Ángeles Moreno, MD · Principal investigator
  • Hospitalario Universitario A Coruña
    A Coruña, La Coruña 15006, Spain
    Recruiting
    • Rosario García Campelo, MD · Contact
    • Rosario García Campelo, MD · Principal investigator
  • Hospital Universitari de Gran Canària Doctor Negrín
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Recruiting
    • David Aguiar Bujanda, MD · Contact
    • David Aguiar Bujanda · Principal investigator
  • Hospital Universitario de León
    León, León 24071, Spain
    Recruiting
    • Soledad Medina, MD · Contact
    • Soledad Medina, MD · Principal investigator
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo 27003, Spain
    Recruiting
    • Begoña Campos, MD · Contact
    • Begoña Campos, MD · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Monica Antoñanzas, MD · Contact
    • Monica Antoñanzas, MD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
    Recruiting
    • Manuel Dómine, MD · Contact
    • Manuel Dómine, MD · Principal investigator
  • Hospital Universitario la Paz
    Madrid, Madrid 28046, Spain
    Recruiting
    • Javier De Castro, MD · Contact
    • Javier De Castro, MD · Principal investigator
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Mariano Provencio, MD · Contact
    • Mariano Provencio, MD · Principal investigator
  • Hospital de Son Espases
    Palma de Mallorca, Mallorca 07120, Spain
    Recruiting
    • Aitor Azkárate Martínez, MD · Contact
    • Aitor Azkárate Martínez, MD · Principal investigator
  • Hospital Santa María Nai
    Ourense, Ourense 32005, Spain
    Recruiting
    • Karmele Areses, MD · Contact
    • Karmele Areses · Principal investigator
  • Hospital Universitari Son Llatzer
    Palma de Mallorca, Palma de Mallorca 07198, Spain
    Recruiting
    • Juan Coves Sarto, MD · Contact
    • Juan Coves Sarto, MD · Principal investigator
  • Complejo Hospitalario Universitario de Vigo
    Vigo, Pontevedra 36036, Spain
    Recruiting
    • Gerardo Huidobro, MD · Contact
    • Gerardo Huidobro, MD · Principal investigator
  • Hospital Universitario Salamanca
    Salamanca, Salamanca 37007, Spain
    Recruiting
    • Alejandro Olivares Hernández, MD · Contact
    • Alejandro Olivares Hernández, MD · Principal investigator
  • Hospital Universitario Nuestra Señora La Candelaria
    Santa Cruz de Tenerife, Santa Cruz de Tenerife 38009, Spain
    Recruiting
    • Karla Mercedes Medina, MD · Contact
    • Karla Mercedes Medina, MD · Principal investigator
  • Hospital Virgen del Rocío
    Seville, Sevilla 41013, Spain
    Recruiting
    • Reyes Bernabé, MD · Contact
    • Reyes Bernabé, MD · Principal investigator
  • Hospital Universitari Sant Joan de Reus
    Reus, Tarragona 43204, Spain
    Recruiting
    • Clara Lucía Gozálvez, MD · Contact
    • Clara Lucía Gozálvez, MD · Principal investigator
  • Consorci Sanitari de Terrassa
    Terrassa, Terrassa 08227, Spain
    Recruiting
    • Remei Blanco, MD · Contact
    • Remei Blanco, MD · Principal investigator
  • Hospital Clínico de Valencia
    Valencia, Valencia 46010, Spain
    Recruiting
    • Amelia Insa, MD · Contact
    • Amelia Insa, MD · Principal investigator
  • Hospital Universitario La Fe
    Valencia, Valencia 46026, Spain
    Recruiting
    • Oscar Juan-Vidal, MD · Contact
    • Oscar Juan-Vidal, MD · Principal investigator
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Valladolid 47003, Spain
    Recruiting
    • Rafael López, MD · Contact
    • Rafael López, MD · Principal investigator
  • Hospital San Cecilio
    Granada, Spain
    Recruiting
    • Silvia Sequero, MD · Contact
  • Hospital Miguel Servet
    Zaragoza, Spain
    Not yet recruiting
    • Joaquin Gimeno, MD · Contact
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2031, 81 months after the start.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's planned 81 months is close to that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 28, 2024
StartActual
Feb 4, 2025
Primary completionEst.
Nov 30, 2031
CompletionEst.
Nov 30, 2031
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06431633
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Feb 4, 2025
Primary completion
Nov 30, 2031 (estimated)
Completion
Nov 30, 2031 (estimated)
Last update
May 18, 2026

Study contacts

Eva Pereira
Contact
gecp@gecp.org
+34 934302006
Mariano Provencio, MD
study chair · President of Fundacion GECP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zimberelimab · Sacituzumab govitecan

Start the discussion